Co-Diagnostics, Inc. CEO Interviewed on Fox Business with Maria Bartiromo as Coronavirus Concerns Rise
January 30 2020 - 11:20AM
Business Wire
Interviews on Fox Business and other
programs discussed issues surrounding the novel strain of the
coronavirus and the Company’s plan to provide a diagnostic
solution
The CEO of Co-Diagnostics, Inc. (Nasdaq:CODX), a
molecular diagnostics company with a unique, patented platform for
the development of diagnostic tests, has recently participated in
interviews with hosts of programs on Fox Business and Yahoo!
Finance to discuss the current outbreak of the novel coronavirus
that originated in China and continues to raise concerns
worldwide.
Currently, the number of confirmed infections in China have
surpassed 7,700, quadrupling since the weekend, and caused 170
deaths. According to the Centers for Disease Control and
Prevention, cases of the new coronavirus, “2019-nCoV,” have been
confirmed in 19 countries since the virus was first identified in
China on January 7, 2020, including 5 positive infections in the US
and suspected cases in 36 states.
Topics in the interviews on Fox Business and Yahoo! Finance
ranged from issues related to detecting the virus, the importance
of a quality diagnostic, and Company competitive advantages and
infrastructure that the Company will leverage to bring the product
to market.
Regarding the interviews, Co-Diagnostics CEO Dwight Egan
commented, “We believe that the competitive advantages of our
CoPrimer™ technology platform and rapid development process have
positioned the Company to provide a high-quality, economic solution
to this ongoing health crisis.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release may include statements regarding the (i) use of
funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in certain verticals or markets, (iv)
capital resources and runway needed to advance the Company’s
products and markets, (v) increased sales in the near-term, (vi)
flexibility in managing the Company’s balance sheet, (vii)
anticipation of business expansion, and (viii) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200130005639/en/
Andrew Benson Co-Diagnostics Investor Relations 801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024